BRCA2 and cancer: In the largest pan-cancer analysis of BRCA1/2 alterations published to date [24] (including 7186 prostate cancers), it was shown that germline mutations were present in 35% of patients with BRCA1-altered mCRPC compared with 50% of patients with BRCA2 altered mCRPC.